Pulmonx Corp. (LUNG): Price and Financial Metrics
GET POWR RATINGS... FREE!
LUNG Stock Price Chart Interactive Chart >
LUNG Price/Volume Stats
| Current price | $39.08 | 52-week high | $69.48 |
| Prev. close | $38.99 | 52-week low | $35.81 |
| Day low | $38.40 | Volume | 381,552 |
| Day high | $39.39 | Avg. volume | 347,359 |
| 50-day MA | $39.30 | Dividend yield | N/A |
| 200-day MA | $48.00 | Market Cap | 1.43B |
Pulmonx Corp. (LUNG) Company Bio
Pulmonx Corp. provides interventional pulmonology, planning tools, and treatments for obstructive lung diseases. It carries out its operations in the following geographical locations: Europe, Middle East and Africa (EMEA), Asia Pacific, Other International, and United States. It offers the Zephyr Endobronchial Valve, an implantable device used to occlude all airways feeding the hyperinflated lobe of a lung that is most diseased with emphysema. It also offers StratX Lung Analysis, a platform designed to treat severe emphysema, and the Chartis Assessment System, a pulmonary assessment system. The company was founded by Rodney C. Perkins and is headquartered in Redwood City, CA.
Latest LUNG News From Around the Web
Below are the latest news stories about Pulmonx Corp that investors may wish to consider to help them evaluate LUNG as an investment opportunity.
3 Healthcare Stocks That Might Skyrocket When COVID Is OverStocks of biotech companies fighting COVID-19 have been great investments over the last two years. What stocks might zoom higher when the pandemic is over? |
Pulmonx to Present at Upcoming September Investor ConferencesREDWOOD CITY, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (Pulmonx) today announced the company will be participating in fireside chats at two upcoming virtual investor conferences. Pulmonx management is scheduled to participate in the 2021 Virtual Wells Fargo Healthcare Conference on Thursday, September 9, 2021 at 7:00am PT / 10:00am ET and the Morgan Stanley 19 th Annual Global Healthcare Conference on Monday, September 13, 2021 at 1:15pm PT / 4:15pm ET. |
Pulmonx Announces Anthem Blue Cross Blue Shield Now Provides Coverage for Severe COPD/Emphysema TreatmentREDWOOD CITY, Calif.--(BUSINESS WIRE)---- $LUNG #COPD--Positive Coverage Policy Gives Additional 34 Million People Access to Treatment with the Zephyr® Valve, a Minimally Invasive Treatment Option |
Pulmonx Corporation (LUNG) Q2 2021 Earnings Call TranscriptLUNG earnings call for the period ending June 30, 2021. |
Pulmonx Reports Second Quarter 2021 Financial ResultsREDWOOD CITY, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (Pulmonx or the "Company"), a global leader in minimally invasive treatments for severe lung disease, today reported financial results for the second quarter ended June 30, 2021. |
LUNG Price Returns
| 1-mo | 4.52% |
| 3-mo | -7.37% |
| 6-mo | -26.12% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -43.38% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...